FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-010

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	or Sec	tion 30(h) of	the Investment Company Act of	1940					
1. Name and Address of Reporting Person* MIDDLETON FRED A	2. Date of Event Requiring Statement (Month/Day/Year) 08/11/2004		3. Issuer Name and Ticker or Trading Symbol Stereotaxis, Inc. [STXS]						
(Last) (First) (Middle) 400 SOUTH EL CAMINO RD SUITE 1200	_ 00/11/2004		Relationship of Reporting Per (Check all applicable) X Director Officer (give title below)	son(s) to Issue 10% Owne Other (spe below)	er (Mo	If Amendment, Date of Original Filed (Month/Day/Year) Individual or Joint/Group Filing (Check Applicable Line)			
(Street) SAN MATEO CA 99402	-		Selow)	Bolowy		Y Form filed b	by One Reporting Person by More than One Person		
(City) (State) (Zip)									
	Table I - No	1	tive Securities Beneficia	-					
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)		Form: Direct (D) (Instr. 5) or Indirect (I)		t Beneficial Ownership		
Common Stock			48,005	D					
Common Stock			32,355	I	Sanderling Ventu		re Partners II, L.P.		
Common Stock			12,119	I		Sanderling Management Limite FBO Sanderling Ventures Limit			
Common Stock			3,029	I	Sanderling Manage FBO Middleton-Mo		gement Limited, Cust McNeil, L.P.		
			e Securities Beneficially ants, options, convertibl		s)				
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable an Expiration Date (Month/Day/Year)		d 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
	Date Exercisable	Expiratior Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)			
Stock Option (right to buy)	09/23/2004	09/23/2013	Common Stock	12,500	5.94	D			
Stock Option (right to buy)	05/26/2005	05/26/2014	Common Stock	12,500	7.02	D			
Series A Convertible Preferred Stock	(1)	(1)	Common Stock	41,335	(2)	D			
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	10,023	(2)	D			
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	2,215	(2)	D			
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	1,389	(2)	D			
Series D-1 Convertible Preferred Stock	(1)	(1)	Common Stock	246	(2)	D			
Series A Convertible Preferred Stock	(1)	(1)	Common Stock	433,709	(2)	I	Sanderling Ventures Partners II, L.P.		
Series A Convertible Preferred Stock	(1)	(1)	Common Stock	167,750	(2)	I	Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.		
Series A Convertible Preferred Stock	(1)	(1)	Common Stock	41,938	(2)	I	Sanderling Management Limited, Cust. FBC Middleton-McNeil, L.P.		
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	228,875	(2)	I	Sanderling Ventures Partners II, L.P.		

(e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and 3. Title and Amount of Securities 4. 5. 6. Nature of Indirect								
1. Title of Derivative Security (Instr. 4)	2. Date Exerc Expiration D (Month/Day/	ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	87,950	(2)	I	Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.	
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	21,987	(2)	I	Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	297,636	(2)	I	Sanderling IV Biomedical Co- Investment Fund, L.P.	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	478	(2)	I	Sanderling V Beteiligungs GmbH & Co. KG	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	1,993	(2)	I	Sanderling V Biomedical Co- Investment Fund, L.P>	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	548	(2)	I	Sanderling V Limited Partnership	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	52,925	(2)	I	Sanderling Venture Partners II, L.P.	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	185,765	(2)	I	Sanderling Venture Partners IV Co- Investment Fund, L.P.	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	3,288	(2)	I	Sanderling Venture Partners V Co- Investment Fund, L.P.	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	19,441	(2)	I	Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	3,527	(2)	I	Sanderling Venture Management V	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	4,860	(2)	I	Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.	
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	166,410	(2)	I	Sanderling IV Biomedical Co- Investment Fund, L.P.	
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	33,186	(2)	I	Sanderling Venture Partners II, L.P.	
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	38,402	(2)	I	Sanderling Venture Partners IV Co- Investment Fund, L.P.	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	2. Date Exerc Expiration D (Month/Day/	ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	12,190	(2)	I	Sanderling Management Limited, Cust. FBO Sandlering Ventures Limited, L.P.	
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	3,047	(2)	I	Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.	
Series D-1 Convertible Preferred Stock	(1)	(1)	Common Stock	33,455	(2)	I	Sanderling V Beteiligungs GmbH & Co. KG	
Series D-1 Convertible Preferred Stock	(1)	(1)	Common Stock	139,397	(2)	I	Sanderling V Biomedical Co- Investment Fund, L.P.	

Explanation of Responses:

- 1. All Series of the Issuer's Convertible Preferred Stock are convertible into common stock upon demand at any time.
- 2. 1-for-3.6.

Remarks:

This is the first of three Forms 3 filed by the reporting person on the August 11, 2004.

<u>/s/ Fred A. Middleton</u> <u>08/04/2004</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.